BACKGROUND: Hepatic epithelioid hemangioendothelioma (PHEHE) is a multifocal, low-grade malignant neoplasia characterized by its epithelial-like appearance and vascular endothelial histogenesis. The outcome of 16 patients treated with orthotopic liver transplantation (OLT) is the subject of this report. METHODS: A retrospective study of 16 patients with HEHE (7 men, 9 women) with ages ranging from 24 to 58 years (mean 37 +/- 10.6 years). Follow-up intervals ranged from 1 to 15 years (median of 4.5 years). RESULTS: Actual patient survival at 1, 3, and 5 years was 100, 87.5, and 71.3%, respectively. Disease-free survival at 1, 3, and 5 years was 81.3, 68.8, and 60.2%, respectively. The 90-day operative mortality was 0. Involvement of the hilar lymph nodes or vascular invasion did not affect survival. The 5-year survival of HEHE compares favorably with that of hepatocellular carcinoma at the same stage (stage 4A): 71.3 versus 9.8% (p = 0.001) CONCLUSIONS: The long-term survival obtained in this series justifies OLT for these tumors even in the presence of limited extrahepatic disease.
BACKGROUND:Hepatic epithelioid hemangioendothelioma (PHEHE) is a multifocal, low-grade malignant neoplasia characterized by its epithelial-like appearance and vascular endothelial histogenesis. The outcome of 16 patients treated with orthotopic liver transplantation (OLT) is the subject of this report. METHODS: A retrospective study of 16 patients with HEHE (7 men, 9 women) with ages ranging from 24 to 58 years (mean 37 +/- 10.6 years). Follow-up intervals ranged from 1 to 15 years (median of 4.5 years). RESULTS: Actual patient survival at 1, 3, and 5 years was 100, 87.5, and 71.3%, respectively. Disease-free survival at 1, 3, and 5 years was 81.3, 68.8, and 60.2%, respectively. The 90-day operative mortality was 0. Involvement of the hilar lymph nodes or vascular invasion did not affect survival. The 5-year survival of HEHE compares favorably with that of hepatocellular carcinoma at the same stage (stage 4A): 71.3 versus 9.8% (p = 0.001) CONCLUSIONS: The long-term survival obtained in this series justifies OLT for these tumors even in the presence of limited extrahepatic disease.
Authors: T E Starzl; S Iwatsuki; C O Esquivel; S Todo; I Kam; S Lynch; R D Gordon; B W Shaw Journal: Semin Liver Dis Date: 1985-11 Impact factor: 6.115
Authors: I R Marino; S Todo; A G Tzakis; G Klintmalm; M Kelleher; S Iwatsuki; T E Starzl; C O Esquivel Journal: Cancer Date: 1988-11-15 Impact factor: 6.860
Authors: S Iwatsuki; T E Starzl; D G Sheahan; I Yokoyama; A J Demetris; S Todo; A G Tzakis; D H Van Thiel; B Carr; R Selby Journal: Ann Surg Date: 1991-09 Impact factor: 12.969
Authors: K Abu-Elmagd; J Fung; J Reyes; A Rao; A Jain; G Mazariegos; W Marsh; J Madariaga; I Dvorchik; J Bueno; J Rogers; J McMichael; F Dodson; H Vargus; J Martin; A Slivka; V Balan; R Corry; J Rakela; N Murase; J Demetris; S Iwatsuki; T Starzl Journal: Clin Transpl Date: 1998
Authors: Joel A Rodriguez; Natasha S Becker; Christine A O'Mahony; John A Goss; Thomas A Aloia Journal: J Gastrointest Surg Date: 2007-08-21 Impact factor: 3.452
Authors: Carmine G Nudo; Eric M Yoshida; Vincent G Bain; Denis Marleau; Phil Wong; Paul J Marotta; Eberhard Renner; Kymberly D Watt; Marc Deschênes Journal: Can J Gastroenterol Date: 2008-10 Impact factor: 3.522
Authors: Christina Hackl; Hans J Schlitt; Gabriele I Kirchner; Birgit Knoppke; Martin Loss Journal: World J Gastroenterol Date: 2014-05-14 Impact factor: 5.742